Effects of salmon calcitonin in postmenopausal osteoporosis: A controlled double-blind clinical study
- 91 Downloads
In this paper we present the results of a 12-month double-blind clinical multicenter study assessing the effects of synthetic salmon cacitonin (CT) administration in a group of white postmenopausal osteoporotic women. Treated patients were given 100 MRC units of synthetic salmon CT injected i.m. in the morning every other day. Control patients received a placebo injection. All patients received 500 mg of elementary calcium p.o., b.i.d. Bone mineral content (BMC) was measured at the extreme distal radius of the nondominant arm by a dual photon bone densitometer which utilizes two radionuclides,241Am and125I, with energies of about 60 keV and 30 keV respectively. Biochemical parameters of calcium-phosphorus metabolism were also measured. After 12 months of treatment a significant mean increment of BMC and nondialyzable OHPr/creatinine values and a significant decrease of total OHPr/creatinine values were observed in the treated group, while controls showed a significant decrease in BMC values. These results, together with the observation that in some patients the decrease in total OHPr/creatinine values was not accompanied by an increment of BMC, show that long-term salmon CT treatment may be of benefit in postmenopausal osteoporosis and that the effects of CT on bone mass may be due not only to the inhibition of bone resorption but also to the stimulation of bone formation.
Key wordsPostmenopausal osteoporosis Calcitonin Bone mineral content
Unable to display preview. Download preview PDF.
- 2.Wallach S, Cohn SH, Atkins HL, Ellis KJ, Kohberger R, Aloia JF, Zanzi I (1977) Effects of salmon calcitonin on skeletal mass in osteoporosis. Curr Therapeutic Res 22:556–572Google Scholar
- 4.Jowsey J, Riggs BL, Kelly PJ, Hoffman DL (1978) Calcium and salmon calcitonin in treatment of osteoporosis. J Clin Endocrinol Met 47:633–639Google Scholar
- 6.Hodgkinson A, Knowles CF (1967) Laboratory Methods. In: Nordin BEC (ed) Calcium, phosphate and magnesium metabolism. Churchill-Livingstone, London, pp 525–564Google Scholar
- 8.Agrawal R, Wallach S, Cohn S, Tessier M, Verch R, Hussain M, Zanzi I (1981) Calcitonin treatment of osteoporosis. In: Pecile A (ed) Calcitonin 1980: chemistry, physiology, pharmacology and clinical aspects. Excerpta Medica, Amsterdam, pp 237–246Google Scholar
- 10.Mazess BR (1983) The noninvasive measurement of skeletal mass. In: Peck WA (ed) Bone and mineral research. Annual 1, Excerpta Medica, Amsterdam, pp 223–279Google Scholar
- 13.Krolner B, Pors Nilsen S, Jacobsen S (1982) Lumbar spine bone mineral content and osteoporosis. In: Menczel J, Robin GC, Makin M, Steimberg R (eds) Osteoporosis. J Wiley and Sons Ltd., New York, pp 87–90Google Scholar
- 14.Orimo H (1984) Recent advances in the treatment of senile osteoporosis. In: Cohn DV, Potts JT Jr, Fujita T (eds) Endocrine control of bone and calcium metabolism. Elsevier Science Publishers, Amsterdam, pp 292–295Google Scholar
- 15.Caniggia A, Gennari C, Bencini M, Cesari L, Borrello G (1970) Calcium metabolism and 47 calcium kinetics before and after long-term thyrocalcitonin treatment in senile osteoporosis. Clin Sci 38:397–407Google Scholar
- 16.Chesnut III CH, Baylink DJ, Gruber HE, Ivey JL, Matthews M, Sisom K, Nelp WB (1981) Treatment of postmenopausal osteoporosis with salmon calcitonin: preliminary results. In: De Luca HF, Frost HM, Jee WSS, Johnston CC Jr, Parfitt AM (eds) Osteoporosis. University Park Press, Baltimore, pp 411–418Google Scholar
- 17.Chesnut III CH, Baylink DJ, Roos BA, Gruber HE, Ivey JL, Matthews M, Nelp WB, Sisom K (1981) Calcitonin and postmenopausal osteoporosis In: Pecile A (ed) Calcitonin 1980, chemistry, physiology, pharmacology and clinical aspects, Excerpta Medica, Amsterdam, pp 247–255Google Scholar